Premium
Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?
Author(s) -
Prussick R.B.,
Miele L.
Publication year - 2018
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.16239
Subject(s) - psoriasis , medicine , nonalcoholic fatty liver disease , adipokine , proinflammatory cytokine , adiponectin , systemic inflammation , insulin resistance , inflammation , population , fatty liver , immunology , comorbidity , disease , gastroenterology , insulin , environmental health
Summary Patients with psoriasis are at an increased risk for nonalcoholic fatty liver disease ( NAFLD ) compared with the general population. However, the pathophysiology underlying this comorbidity and elucidation of effective treatment strategies are unclear. This review provides insights into the possible role of chronic, low‐grade inflammation in the pathogenesis of NAFLD in patients with psoriasis. Both conditions are associated with increased levels of proinflammatory adipokines (such as tumour necrosis factor‐α and interleukin‐6) and hepatokines, and decreased levels of adiponectin, an anti‐inflammatory adipokine. This imbalance in inflammatory mediators could result in insulin resistance and, thereby, facilitate the occurrence and progression of NAFLD in a multistep manner. All patients with psoriasis should, therefore, be considered candidates for NAFLD screening and managed accordingly. Given the common aetiology of inflammation between these conditions, it is hypothesized that biological therapies for psoriasis may attenuate the systemic inflammatory process and progression of NAFLD in patients with psoriasis.